Sector: MedicalOMPI (NASDAQ: OMPI)
Ranking History
Scan Date: | 10/27/2009 |
Sector: | Medical |
Funamental : | 150 |
Technical : | 230 |
Performance : | 149 |
Overall: | 209 |
Number of Stocks: | 306 |
Scan Date: | 10/20/2009 |
Sector: | Medical |
Funamental : | 154 |
Technical : | 241 |
Performance : | 128 |
Overall: | 212 |
Number of Stocks: | 305 |
Scan Date: | 10/15/2009 |
Sector: | Medical |
Funamental : | 157 |
Technical : | 235 |
Performance : | 116 |
Overall: | 201 |
Number of Stocks: | 305 |
Headlines
- CEL-SCI's H1N1 Clinical Study News Seen as Credibility Booster
Nov 06, 2009 02:39 PM | CVM, OMPI, ZGEN
- Obagi Medical Products Reports Third Quarter 2009 Earnings
Nov 05, 2009 04:15 PM | OMPI
- Obagi Medical Products to Report Third Quarter 2009 Financial Results and Host a Conference Call on November 5, 2009
Oct 19, 2009 04:53 PM | OMPI
- Obagi Medical Products to Present at The UBS Life Science Conference
Sep 18, 2009 01:06 PM | OMPI, UBS
- In Search of Healthcare Diamonds In The Rough
Jan 12, 2009 12:57 AM | ACHN, AKRX, BPA, CYNO, DNA, ENDP
- Obagi Medical rises on analyst 'Buy' rating and Vista Partners Initiates Coverage on Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE)
May 21, 2008 09:29 AM | IDEV, OMPI
- Obagi Medical rises on analyst 'Buy' rating and Vista Partners Initiates Coverage on Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE)
May 21, 2008 09:29 AM | IDEV, OMPI
- Obagi Medical: Actionable Trading Call!
Apr 28, 2008 10:30 AM | JNJ, MNT, OMPI
- Earnings, Oil Prices, & Bernanke
Oct 16, 2007 12:24 PM | AAUK, ACGY, ALTR, AMZN, BIIB, BSC
- Obagi Medical Products Reports Second Quarter 2009 Financial Results
Aug 06, 2009 04:37 PM | OMPI
- Obagi Medical Products Reveals Results of a Meta-Analysis Comparing the Company’s Novel 5 Percent Solubilized BPO to Other Prescription 5 Percent BPO and Combination BPO/Clindamycin Topical Products
Jul 30, 2009 07:09 AM | OMPI
- Obagi Medical Products’ CLENZIderm M.D. Serum Gel Significantly Reduces Non-Inflammatory Lesions with Visible Results as Early as Week One
Jul 30, 2009 07:08 AM | OMPI
- Obagi Medical Products Releases Results of a Clinical Trial Showing Optimized Patient Outcomes When Condition & Enhance System is Used in Combination with Botulinum Toxin Type A
Jul 30, 2009 07:05 AM | OMPI
- Obagi Medical Products to Present at the 29th Annual Canaccord Adams Global Growth Conference in August
Jul 28, 2009 04:35 PM | OMPI
- Obagi Medical Products to Report Second Quarter 2009 Financial Results and Host a Conference Call on August 6
Jul 14, 2009 04:33 PM | OMPI
- Obagi Medical Products Reports First Quarter 2009 Financial Results
May 07, 2009 04:44 PM | OMPI
- Obagi Medical Products to Report First Quarter 2009 Financial Results and Host a Conference Call on May 7
Apr 28, 2009 04:27 PM | OMPI
- New Survey Reveals Women Are Still Spending Money on In-Office Procedures and Skin Care Despite Current Economy
Apr 23, 2009 07:14 AM | OMPI
- Obagi Medical Products, Inc. Focuses on the Physician Dispense Market and Discontinues Distribution in the Pharmacy Channel
Apr 13, 2009 04:54 PM | OMPI
- Form 4 DUERDEN JOHN H For: Jun 18 (10K)
Jun 22, 2009 04:16 PM
- Form 4 Bartholdson John A. For: Jun 18 (10K)
Jun 22, 2009 03:50 PM
- Form 4 Obagi Medical Products, For: Jun 18 Filed by: FITZGIBBONS ALBERT J III (10K)
Jun 22, 2009 03:30 PM
- Form 4 BADIE RONALD P For: Jun 18 (10K)
Jun 22, 2009 03:28 PM
- Form 4 Grant Edward A For: Jun 18 (10K)
Jun 22, 2009 03:22 PM
- Form 4 HUMMEL ALBERT F For: Jun 18 (10K)
Jun 22, 2009 03:18 PM
- Form 4 Hunter Laura B. For: Mar 03 (10K)
Mar 05, 2009 03:02 PM
- Form 4 Romm Preston S For: Mar 03 (10K)
Mar 05, 2009 02:59 PM
- Form 4 Goldstein David S. For: Mar 03 (10K)
Mar 05, 2009 02:59 PM
- Form 4 Carlson Steve R. For: Mar 03 (10K)
Mar 05, 2009 02:59 PM
Analyst Ratings
Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
Share Performance
|
Period
|
OMPI
|
Compare to S&P
|
| YTD |
37.00 %
|
19.42 %
|
| 4 Weeks |
-12.27 %
|
-13.20 %
|
| 12 Weeks |
21.23 %
|
18.23 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 87.50 %
|
|
EPS Growth in Last Year: -25.00 %
|
|
Sales Growth in Last Quarter: 14.39 %
|
|
Sales Growth in Last Quarter: -6.83 %
|
|
